The global Generic Injectables market size was valued at USD 31500 million in 2022 and is forecast to a readjusted size of USD 39670 million by 2029 with a CAGR of 3.3% during review period.
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.
This report is a detailed and comprehensive analysis for global Generic Injectables market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Generic Injectables market size and forecasts, in consumption value ($ Million), 2018-2029
Global Generic Injectables market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Generic Injectables market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Generic Injectables market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Generic Injectables
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Generic Injectables market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Small Molecule
Large Molecule
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Strengths
- Growing demand due to cost-effective alternatives to branded injectables, offering affordability to healthcare systems and patients.
- Strong pipeline development and regulatory approvals, enhancing market accessibility and competition.
Weaknesses
- Regulatory challenges and market entry barriers due to stringent compliance requirements.
- Limited product differentiation leading to intense price competition, affecting profit margins.
Opportunities
- Expansion in emerging markets with increasing healthcare access and cost-conscious patients.
- Advancements in drug formulation and delivery technologies, improving the efficiency of generic injectables.
Threats
- Intellectual property challenges from branded drug manufacturers, resulting in patent disputes and litigation.
- Potential supply chain disruptions due to reliance on raw materials and manufacturing processes in global markets.
Political
- Government regulations and policies in healthcare funding and reimbursement can influence market dynamics and accessibility.
- Ongoing political pressures for cost reduction in healthcare systems may boost the demand for generics over branded drugs.
Economic
- Economic downturns can drive the demand for cost-effective generic injectables as healthcare costs become a greater concern for patients and insurers.
- Exchange rate fluctuations and global supply chain economics could impact the pricing and profitability of generic injectables.
Social
- Increasing public awareness about the benefits of generic drugs can drive adoption of generic injectables over branded alternatives.
- Rising healthcare demands in aging populations globally will increase the need for affordable injectable treatments.
Technological
- Advancements in manufacturing and drug delivery technologies can improve the quality and efficiency of generic injectables.
- Ongoing research and development into new formulations may allow generic injectables to expand into new therapeutic areas.
Environmental
- Sustainability concerns in manufacturing processes could lead to increased pressure on pharmaceutical companies to adopt eco-friendly production methods.
- Global supply chain disruptions, particularly environmental crises, could impact the availability and cost of raw materials for injectables.
Legal
- Stringent regulatory approvals and intellectual property laws can delay the market entry of generic injectables.
- Patent expirations and litigation over drug patents can create opportunities and risks for generic injectables market growth.
Suppliers
- Raw material suppliers providing active pharmaceutical ingredients (APIs) and excipients crucial for injectable formulations.
- Contract manufacturers and pharmaceutical companies ensuring production capacity and compliance with regulatory standards.
Inputs
- Regulatory approvals, including manufacturing standards and product certifications, are necessary for market entry.
- Technological advancements in drug formulation and delivery systems that enhance the efficacy of generic injectables.
Processes
- Manufacturing processes for the development and production of generic injectables under Good Manufacturing Practices (GMP) guidelines.
- Quality control and testing procedures to ensure safety, efficacy, and compliance with regulatory standards.
Outputs
- High-quality generic injectable drugs that meet patient and healthcare provider demand at a lower cost compared to branded versions.
- Regulatory certifications and market approvals that facilitate product availability across different regions.
Customers
- Hospitals, clinics, and healthcare providers who prescribe generic injectables to patients for cost-effective treatment options.
- Pharmaceutical wholesalers and distributors that handle the logistics and supply of generic injectables to pharmacies and healthcare facilities.
Threat of New Entrants
- High regulatory barriers and the need for substantial capital investment in manufacturing facilities make market entry challenging for new players.
- However, growing demand for cost-effective healthcare solutions encourages some new companies to explore opportunities in generic injectables.
Bargaining Power of Suppliers
- A limited number of suppliers for key raw materials, such as active pharmaceutical ingredients (APIs), increases supplier power.
- Reliance on contract manufacturers for production can also give suppliers leverage in terms of cost and production timelines.
Bargaining Power of Buyers
- Healthcare providers and governments, as large buyers, have significant bargaining power due to their ability to negotiate lower prices for generic injectables.
- Price sensitivity in the healthcare sector further strengthens the bargaining power of buyers, pushing for more affordable generics.
Threat of Substitutes
- The availability of alternative treatment options, such as oral medications or biologics, may reduce demand for certain injectable generics.
- However, the increasing need for injectables in specific therapeutic areas (e.g., cancer, diabetes) mitigates the threat of substitutes.
Industry Rivalry
- Intense competition among established generic injectable manufacturers and new entrants leads to price wars and reduced profit margins.
- Ongoing product differentiation through improved formulations and expanded therapeutic applications helps companies stay competitive in the market.
Raw Materials
- The sourcing of active pharmaceutical ingredients (APIs) and excipients is critical, with fluctuations in the quality and cost of these raw materials impacting production.
- Limited availability of high-quality, cost-effective raw materials can disrupt production timelines and increase costs for generic injectables.
Manufacturing
- Contract manufacturing organizations (CMOs) play a significant role in scaling production, which affects the capacity and flexibility of generic injectable manufacturers.
- Investment in state-of-the-art manufacturing technologies and compliance with stringent regulatory standards ensures product quality and market competitiveness.
R&D and Innovation
- Research and development efforts focus on improving drug delivery systems, enhancing the stability of injectables, and reducing production costs.
- Innovation in formulation and packaging technologies drives differentiation in the market, helping companies maintain a competitive edge.
Production and Manufacturing
- Generic injectable manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory standards to ensure product quality and market acceptance.
- Scaling production to meet global demand while maintaining cost-effectiveness is a significant challenge for midstream players in the supply chain.
Quality Control and Testing
- Rigorous quality control measures, including stability and sterility testing, are essential to ensure the safety and efficacy of generic injectables.
- Midstream players must invest in modern testing facilities to meet both regulatory requirements and market expectations for product consistency.
Distribution and Logistics
- Efficient distribution networks are essential to ensure timely delivery of generic injectables to healthcare facilities, pharmacies, and patients across regions.
- Managing global logistics to overcome challenges such as regulatory compliance and transportation costs is critical for maintaining product availability.
Market Access and Sales
- Strong relationships with healthcare providers, insurers, and government bodies are necessary for gaining market access and ensuring reimbursement for generic injectables.
- Sales strategies must focus on educating healthcare professionals about the cost-effectiveness and therapeutic benefits of generic injectables to drive adoption.
Chapter 1, to describe Generic Injectables product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Generic Injectables, with revenue, gross margin and global market share of Generic Injectables from 2018 to 2023.
Chapter 3, the Generic Injectables competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Generic Injectables market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Generic Injectables.
Chapter 13, to describe Generic Injectables research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Generic Injectables
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Generic Injectables by Type
1.3.1 Overview: Global Generic Injectables Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Generic Injectables Consumption Value Market Share by Type in 2022
1.3.3 Small Molecule
1.3.4 Large Molecule
1.4 Global Generic Injectables Market by Application
1.4.1 Overview: Global Generic Injectables Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Oncology
1.4.3 Anesthesia
1.4.4 Anti-Infectives
1.4.5 Parenteral Nutrition
1.4.6 Cardiovascular Diseases
1.5 Global Generic Injectables Market Size & Forecast
1.6 Global Generic Injectables Market Size and Forecast by Region
1.6.1 Global Generic Injectables Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Generic Injectables Market Size by Region, (2018-2029)
1.6.3 North America Generic Injectables Market Size and Prospect (2018-2029)
1.6.4 Europe Generic Injectables Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Generic Injectables Market Size and Prospect (2018-2029)
1.6.6 South America Generic Injectables Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Generic Injectables Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Hospira (Pfizer Inc.)
2.1.1 Hospira (Pfizer Inc.) Details
2.1.2 Hospira (Pfizer Inc.) Major Business
2.1.3 Hospira (Pfizer Inc.) Generic Injectables Product and Solutions
2.1.4 Hospira (Pfizer Inc.) Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Hospira (Pfizer Inc.) Recent Developments and Future Plans
2.2 Fresenius Kabi
2.2.1 Fresenius Kabi Details
2.2.2 Fresenius Kabi Major Business
2.2.3 Fresenius Kabi Generic Injectables Product and Solutions
2.2.4 Fresenius Kabi Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Fresenius Kabi Recent Developments and Future Plans
2.3 Sandoz (Novartis)
2.3.1 Sandoz (Novartis) Details
2.3.2 Sandoz (Novartis) Major Business
2.3.3 Sandoz (Novartis) Generic Injectables Product and Solutions
2.3.4 Sandoz (Novartis) Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sandoz (Novartis) Recent Developments and Future Plans
2.4 Hikma Pharmaceuticals PLC
2.4.1 Hikma Pharmaceuticals PLC Details
2.4.2 Hikma Pharmaceuticals PLC Major Business
2.4.3 Hikma Pharmaceuticals PLC Generic Injectables Product and Solutions
2.4.4 Hikma Pharmaceuticals PLC Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
2.5 Dr. Reddy’s Laboratories Ltd
2.5.1 Dr. Reddy’s Laboratories Ltd Details
2.5.2 Dr. Reddy’s Laboratories Ltd Major Business
2.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Product and Solutions
2.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments and Future Plans
2.6 Grifols
2.6.1 Grifols Details
2.6.2 Grifols Major Business
2.6.3 Grifols Generic Injectables Product and Solutions
2.6.4 Grifols Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Grifols Recent Developments and Future Plans
2.7 Nichi-Iko Group (Sagent)
2.7.1 Nichi-Iko Group (Sagent) Details
2.7.2 Nichi-Iko Group (Sagent) Major Business
2.7.3 Nichi-Iko Group (Sagent) Generic Injectables Product and Solutions
2.7.4 Nichi-Iko Group (Sagent) Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Nichi-Iko Group (Sagent) Recent Developments and Future Plans
2.8 Teva Pharmaceutical
2.8.1 Teva Pharmaceutical Details
2.8.2 Teva Pharmaceutical Major Business
2.8.3 Teva Pharmaceutical Generic Injectables Product and Solutions
2.8.4 Teva Pharmaceutical Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Teva Pharmaceutical Recent Developments and Future Plans
2.9 Auromedics
2.9.1 Auromedics Details
2.9.2 Auromedics Major Business
2.9.3 Auromedics Generic Injectables Product and Solutions
2.9.4 Auromedics Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Auromedics Recent Developments and Future Plans
2.10 Sanofi
2.10.1 Sanofi Details
2.10.2 Sanofi Major Business
2.10.3 Sanofi Generic Injectables Product and Solutions
2.10.4 Sanofi Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Sanofi Recent Developments and Future Plans
2.11 Gland Pharma
2.11.1 Gland Pharma Details
2.11.2 Gland Pharma Major Business
2.11.3 Gland Pharma Generic Injectables Product and Solutions
2.11.4 Gland Pharma Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Gland Pharma Recent Developments and Future Plans
2.12 Endo International PLC
2.12.1 Endo International PLC Details
2.12.2 Endo International PLC Major Business
2.12.3 Endo International PLC Generic Injectables Product and Solutions
2.12.4 Endo International PLC Generic Injectables Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Endo International PLC Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Generic Injectables Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Generic Injectables by Company Revenue
3.2.2 Top 3 Generic Injectables Players Market Share in 2022
3.2.3 Top 6 Generic Injectables Players Market Share in 2022
3.3 Generic Injectables Market: Overall Company Footprint Analysis
3.3.1 Generic Injectables Market: Region Footprint
3.3.2 Generic Injectables Market: Company Product Type Footprint
3.3.3 Generic Injectables Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Generic Injectables Consumption Value and Market Share by Type (2018-2023)
4.2 Global Generic Injectables Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Generic Injectables Consumption Value Market Share by Application (2018-2023)
5.2 Global Generic Injectables Market Forecast by Application (2024-2029)
6 North America
6.1 North America Generic Injectables Consumption Value by Type (2018-2029)
6.2 North America Generic Injectables Consumption Value by Application (2018-2029)
6.3 North America Generic Injectables Market Size by Country
6.3.1 North America Generic Injectables Consumption Value by Country (2018-2029)
6.3.2 United States Generic Injectables Market Size and Forecast (2018-2029)
6.3.3 Canada Generic Injectables Market Size and Forecast (2018-2029)
6.3.4 Mexico Generic Injectables Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Generic Injectables Consumption Value by Type (2018-2029)
7.2 Europe Generic Injectables Consumption Value by Application (2018-2029)
7.3 Europe Generic Injectables Market Size by Country
7.3.1 Europe Generic Injectables Consumption Value by Country (2018-2029)
7.3.2 Germany Generic Injectables Market Size and Forecast (2018-2029)
7.3.3 France Generic Injectables Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Generic Injectables Market Size and Forecast (2018-2029)
7.3.5 Russia Generic Injectables Market Size and Forecast (2018-2029)
7.3.6 Italy Generic Injectables Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Generic Injectables Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Generic Injectables Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Generic Injectables Market Size by Region
8.3.1 Asia-Pacific Generic Injectables Consumption Value by Region (2018-2029)
8.3.2 China Generic Injectables Market Size and Forecast (2018-2029)
8.3.3 Japan Generic Injectables Market Size and Forecast (2018-2029)
8.3.4 South Korea Generic Injectables Market Size and Forecast (2018-2029)
8.3.5 India Generic Injectables Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Generic Injectables Market Size and Forecast (2018-2029)
8.3.7 Australia Generic Injectables Market Size and Forecast (2018-2029)
9 South America
9.1 South America Generic Injectables Consumption Value by Type (2018-2029)
9.2 South America Generic Injectables Consumption Value by Application (2018-2029)
9.3 South America Generic Injectables Market Size by Country
9.3.1 South America Generic Injectables Consumption Value by Country (2018-2029)
9.3.2 Brazil Generic Injectables Market Size and Forecast (2018-2029)
9.3.3 Argentina Generic Injectables Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Generic Injectables Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Generic Injectables Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Generic Injectables Market Size by Country
10.3.1 Middle East & Africa Generic Injectables Consumption Value by Country (2018-2029)
10.3.2 Turkey Generic Injectables Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Generic Injectables Market Size and Forecast (2018-2029)
10.3.4 UAE Generic Injectables Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Generic Injectables Market Drivers
11.2 Generic Injectables Market Restraints
11.3 Generic Injectables Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Generic Injectables Industry Chain
12.2 Generic Injectables Upstream Analysis
12.3 Generic Injectables Midstream Analysis
12.4 Generic Injectables Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Generic Injectables Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Generic Injectables Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Generic Injectables Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Generic Injectables Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Hospira (Pfizer Inc.) Company Information, Head Office, and Major Competitors
Table 6. Hospira (Pfizer Inc.) Major Business
Table 7. Hospira (Pfizer Inc.) Generic Injectables Product and Solutions
Table 8. Hospira (Pfizer Inc.) Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Hospira (Pfizer Inc.) Recent Developments and Future Plans
Table 10. Fresenius Kabi Company Information, Head Office, and Major Competitors
Table 11. Fresenius Kabi Major Business
Table 12. Fresenius Kabi Generic Injectables Product and Solutions
Table 13. Fresenius Kabi Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Fresenius Kabi Recent Developments and Future Plans
Table 15. Sandoz (Novartis) Company Information, Head Office, and Major Competitors
Table 16. Sandoz (Novartis) Major Business
Table 17. Sandoz (Novartis) Generic Injectables Product and Solutions
Table 18. Sandoz (Novartis) Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Sandoz (Novartis) Recent Developments and Future Plans
Table 20. Hikma Pharmaceuticals PLC Company Information, Head Office, and Major Competitors
Table 21. Hikma Pharmaceuticals PLC Major Business
Table 22. Hikma Pharmaceuticals PLC Generic Injectables Product and Solutions
Table 23. Hikma Pharmaceuticals PLC Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Hikma Pharmaceuticals PLC Recent Developments and Future Plans
Table 25. Dr. Reddy’s Laboratories Ltd Company Information, Head Office, and Major Competitors
Table 26. Dr. Reddy’s Laboratories Ltd Major Business
Table 27. Dr. Reddy’s Laboratories Ltd Generic Injectables Product and Solutions
Table 28. Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Dr. Reddy’s Laboratories Ltd Recent Developments and Future Plans
Table 30. Grifols Company Information, Head Office, and Major Competitors
Table 31. Grifols Major Business
Table 32. Grifols Generic Injectables Product and Solutions
Table 33. Grifols Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Grifols Recent Developments and Future Plans
Table 35. Nichi-Iko Group (Sagent) Company Information, Head Office, and Major Competitors
Table 36. Nichi-Iko Group (Sagent) Major Business
Table 37. Nichi-Iko Group (Sagent) Generic Injectables Product and Solutions
Table 38. Nichi-Iko Group (Sagent) Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Nichi-Iko Group (Sagent) Recent Developments and Future Plans
Table 40. Teva Pharmaceutical Company Information, Head Office, and Major Competitors
Table 41. Teva Pharmaceutical Major Business
Table 42. Teva Pharmaceutical Generic Injectables Product and Solutions
Table 43. Teva Pharmaceutical Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Teva Pharmaceutical Recent Developments and Future Plans
Table 45. Auromedics Company Information, Head Office, and Major Competitors
Table 46. Auromedics Major Business
Table 47. Auromedics Generic Injectables Product and Solutions
Table 48. Auromedics Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Auromedics Recent Developments and Future Plans
Table 50. Sanofi Company Information, Head Office, and Major Competitors
Table 51. Sanofi Major Business
Table 52. Sanofi Generic Injectables Product and Solutions
Table 53. Sanofi Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Sanofi Recent Developments and Future Plans
Table 55. Gland Pharma Company Information, Head Office, and Major Competitors
Table 56. Gland Pharma Major Business
Table 57. Gland Pharma Generic Injectables Product and Solutions
Table 58. Gland Pharma Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Gland Pharma Recent Developments and Future Plans
Table 60. Endo International PLC Company Information, Head Office, and Major Competitors
Table 61. Endo International PLC Major Business
Table 62. Endo International PLC Generic Injectables Product and Solutions
Table 63. Endo International PLC Generic Injectables Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Endo International PLC Recent Developments and Future Plans
Table 65. Global Generic Injectables Revenue (USD Million) by Players (2018-2023)
Table 66. Global Generic Injectables Revenue Share by Players (2018-2023)
Table 67. Breakdown of Generic Injectables by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Generic Injectables, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Generic Injectables Players
Table 70. Generic Injectables Market: Company Product Type Footprint
Table 71. Generic Injectables Market: Company Product Application Footprint
Table 72. Generic Injectables New Market Entrants and Barriers to Market Entry
Table 73. Generic Injectables Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Generic Injectables Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Generic Injectables Consumption Value Share by Type (2018-2023)
Table 76. Global Generic Injectables Consumption Value Forecast by Type (2024-2029)
Table 77. Global Generic Injectables Consumption Value by Application (2018-2023)
Table 78. Global Generic Injectables Consumption Value Forecast by Application (2024-2029)
Table 79. North America Generic Injectables Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Generic Injectables Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Generic Injectables Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Generic Injectables Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Generic Injectables Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Generic Injectables Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Generic Injectables Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Generic Injectables Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Generic Injectables Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Generic Injectables Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Generic Injectables Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Generic Injectables Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Generic Injectables Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Generic Injectables Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Generic Injectables Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Generic Injectables Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Generic Injectables Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Generic Injectables Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Generic Injectables Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Generic Injectables Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Generic Injectables Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Generic Injectables Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Generic Injectables Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Generic Injectables Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Generic Injectables Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Generic Injectables Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Generic Injectables Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Generic Injectables Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Generic Injectables Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Generic Injectables Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Generic Injectables Raw Material
Table 110. Key Suppliers of Generic Injectables Raw Materials
List of Figures
Figure 1. Generic Injectables Picture
Figure 2. Global Generic Injectables Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Generic Injectables Consumption Value Market Share by Type in 2022
Figure 4. Small Molecule
Figure 5. Large Molecule
Figure 6. Global Generic Injectables Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Generic Injectables Consumption Value Market Share by Application in 2022
Figure 8. Oncology Picture
Figure 9. Anesthesia Picture
Figure 10. Anti-Infectives Picture
Figure 11. Parenteral Nutrition Picture
Figure 12. Cardiovascular Diseases Picture
Figure 13. Global Generic Injectables Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Generic Injectables Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Generic Injectables Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Generic Injectables Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Generic Injectables Consumption Value Market Share by Region in 2022
Figure 18. North America Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Generic Injectables Revenue Share by Players in 2022
Figure 24. Generic Injectables Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Generic Injectables Market Share in 2022
Figure 26. Global Top 6 Players Generic Injectables Market Share in 2022
Figure 27. Global Generic Injectables Consumption Value Share by Type (2018-2023)
Figure 28. Global Generic Injectables Market Share Forecast by Type (2024-2029)
Figure 29. Global Generic Injectables Consumption Value Share by Application (2018-2023)
Figure 30. Global Generic Injectables Market Share Forecast by Application (2024-2029)
Figure 31. North America Generic Injectables Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Generic Injectables Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Generic Injectables Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Generic Injectables Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Generic Injectables Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Generic Injectables Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 41. France Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Generic Injectables Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Generic Injectables Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Generic Injectables Consumption Value Market Share by Region (2018-2029)
Figure 48. China Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 51. India Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Generic Injectables Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Generic Injectables Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Generic Injectables Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Generic Injectables Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Generic Injectables Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Generic Injectables Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Generic Injectables Consumption Value (2018-2029) & (USD Million)
Figure 65. Generic Injectables Market Drivers
Figure 66. Generic Injectables Market Restraints
Figure 67. Generic Injectables Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Generic Injectables in 2022
Figure 70. Manufacturing Process Analysis of Generic Injectables
Figure 71. Generic Injectables Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
